z-logo
Premium
Genome‐wide association studies and polygenic risk scores for skin cancer: clinically useful yet?
Author(s) -
Roberts M.R.,
Asgari M.M.,
Toland A.E.
Publication year - 2019
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.17917
Subject(s) - genome wide association study , genetic association , melanoma , basal cell carcinoma , skin cancer , medicine , cancer , oncology , biology , bioinformatics , genetics , single nucleotide polymorphism , gene , basal cell , genotype
Summary Background Genome‐wide association studies ( GWAS ) have identified thousands of susceptibility variants, although most have been associated with small individual risk estimates that offer little predictive value. However, combining multiple variants into polygenic risk scores ( PRS ) may be more informative. Multiple studies have developed PRS composed of GWAS ‐identified variants for cutaneous cancers. This review highlights data from these studies. Objectives To review published GWAS and PRS studies for melanoma, cutaneous squamous cell carcinoma ( cSCC ) and basal cell carcinoma ( BCC ), and discuss their potential clinical utility. Methods We searched PubMed and the National Human Genome Research Institute–European Bioinformatics Institute GWAS catalogue to identify relevant studies. Results Results from 21 GWAS (11 melanoma, 3 cSCC , 7 BCC ) and 11 PRS studies are summarized. Six loci in pigmentation genes overlap between these three cancers ( ASIP / RALY , IRF 4 , MC 1R , OCA 2 , SLC 45A2 and TYR ). Additional loci overlap for cSCC / BCC and BCC /melanoma, but no other loci are shared between cSCC and melanoma. PRS for melanoma show roughly two‐to‐threefold increases in risk and modest improvements in risk prediction (2–7% increases). PRS are associated with twofold and threefold increases in risk of cSCC and BCC , respectively, with small improvements (2% increase) in predictive ability. Conclusions Existing data indicate that PRS may offer small, but potentially meaningful, improvements to risk prediction. Additional research is needed to clarify the potential utility of PRS in cutaneous carcinomas. Clinical translation will require well‐powered validation studies incorporating known risk factors to evaluate PRS as tools for screening.What's already known about this topic?Over 50 susceptibility loci for melanoma, basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) have been identified in genome‐wide association studies (GWAS). Polygenic risk scores (PRS) using variants identified from GWAS have also been developed for melanoma, BCC and cSCC, and investigated with respect to clinical risk prediction.What does this study add?This review provides an overview of GWAS findings and the potential clinical utility of PRS for melanoma, BCC and cSCC.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here